Paper
0
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Authors
Published
Nov 17, 2020
Show more
Save
Tip0
TipSave
Abstract
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.